GBR 310

About Glenmark

Glenmark Pharmaceuticals has evolved from its 1977 origins as an Indian generics manufacturer into a global, publicly traded biopharmaceutical enterprise with a strategic U.S. headquarters. The company operates on a hybrid model, combining the stable revenue base of a generics business with targeted R&D investments in novel Respiratory, Dermatology, and Oncology therapies. This strategy is supported by significant global infrastructure, including 11 manufacturing facilities and 6 R&D centers, aiming to deliver both innovative treatments and broad accessibility to patients in over 80 countries.

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals has evolved from its 1977 founding into a diversified, global pharmaceutical enterprise with a strategic focus on innovation and accessibility. Under the leadership of Chairman & Managing Director Glenn Saldanha, the company has built significant capabilities in R&D, biologics, and complex generics, supported by a robust pipeline of 25+ candidates and a global commercial footprint. Its strategy centers on advancing a focused pipeline in respiratory, dermatology, and oncology through its biotech arm Ichnos Glenmark Innovation (IGI), while simultaneously scaling its generics and branded formulations business across emerging and developed markets.

Therapeutic Areas